Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Cambridge University Hospitals NHS Foundation Trust
BioNTech SE
Osaka University
Bristol-Myers Squibb